Biotechnology major Biocon forays into nephrology space

By Staff
|
Google Oneindia News

Bangalore, Mar 09: Biotechnology major Biocon on Thursday forayed into the nephrology space with the launch of a portfolio of five renal therapy products for the domestic and global markets, which it said was cheaper compared to MNC drug prices. The new immunosuppressants for renal therapy are at least 35-40 per cent cheaper than the MNC drug prices in the similar product category, the company's Marketing Head Rakesh Bamzai said.

The Bangalore-headquartered company's Chairman and Managing Director, Kiran Mazumdar-Shaw said for these products, the firm would initially focus on the Indian market and then look at Gulf Cooperation Council countries and neighbouring nations. Bamzai said depending on the regulatory approval, the company would thereafter look at Latin American and South East Asian markets and at a "very later date" highly regulatory markets.

Mazumdar-Shaw said "we will look at overseas markets all the time. But the registration process is quite a lengthy process. In some overseas markets, we may be able to launch in nine months but in many others it will take at least a couple of years." Bamzai said the global nephrology products market size is estimated to be .3 billion, while in India it's Rs 300 crore currently .Biocon has targetted to capture 25 per cent of the marketshare in India in five years, he said. The products were unveiled by Sudha Murthy, Chairperson of Infosys Foundation and wife of Infosys Chief Mentor N R Narayana Murthy, at a press conference.

OneIndia News

For Daily Alerts
Get Instant News Updates
Enable
x
Notification Settings X
Time Settings
Done
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
X